Glomus jugulare tumor: 2026 so far

Evidence broadened from Gamma Knife to multi-technique radiotherapy series.

In the months covered, the evidence widened from mostly Gamma Knife reports to a broader adult routine-care radiation series showing very high local control for non-metastatic head and neck paragangliomas. A single-institution review reported that most tumors were stable or smaller on follow-up imaging (scans that show tumor size). It also reported no severe (grade 3-5) toxicities (serious treatment side effects). In that report, the radiation technique used often reflected tumor size and complexity, rather than being a direct head-to-head comparison of techniques. Earlier in 2026, a 95-person Gamma Knife review similarly reported high tumor control and symptom stability after a single session. In that cohort, younger age was linked to lower tumor control, and earlier-stage tumors did best. This set of reports supports radiation as a commonly used non-surgical option that is often linked with stable scans and generally mild reported side effects in these single-center experiences.

Research covered in: May 2026, September 2026

Pooled evidence added side-effect rates and planning-related failure patterns.

So far in 2026, pooled evidence from a systematic review/meta-analysis (a study that combines results across many studies) reinforced that Gamma Knife radiosurgery (highly focused radiation, usually in one session) usually kept glomus jugulare tumors from growing on follow-up scans. About half showed some shrinkage. In the same pooled reports, new or worsened cranial nerve problems (issues with nerves that control face, swallowing, voice, and hearing) and worsening hearing occurred in a minority of patients. One included cohort described some progressions at the edge of, or outside, the treated area. This adds to a separate single-center review that also reported high tumor and clinical (symptom) control after single-session Gamma Knife, while suggesting outcomes differed by age and tumor stage in that cohort. Taken together, these reports point to Gamma Knife often being linked with stable imaging, while also keeping nerve-related symptoms and hearing changes on the list of possible outcomes for a subset of people.

Research covered in: May 2026, July 2026

Reports clarified independence after surgery alongside advanced-tumor complication risks.

In the months covered, a real-world surgical series provided more concrete outcome details. In that report, many people had good day-to-day function about a year after surgery, and there was no perioperative mortality (death around the time of surgery). At the same time, advanced tumors carried meaningful risks. Gross total resection (removal of all visible tumor) was achieved in just over half of procedures. With longer follow-up, the report included both recurrences after complete removal and progression of residual tumor, which supports ongoing monitoring in some patients. Facial nerve injury was reported in 25% of procedures, was permanent in most affected cases, and in that series was seen only in advanced Fisch C/D tumors. About one-third of procedures included an unplanned return to the operating room. This frames surgery as something many people can recover from with good function, while also showing that nerve injury and additional procedures can be part of the experience, especially with more advanced disease.

Research covered in: June 2026

Imaging work moved from mapping extent to refining radiosurgery targets.

Across January 2026 to September 2026 reports, imaging advances often focused on mapping tumor extent and nearby critical structures more clearly to support treatment planning. One imaging study in surgically confirmed cases reported that a contrast MRI sequence called BRAVO (a specific MRI method that highlights anatomy) matched surgeons well for overall tumor extent. In the same study, CT (a detailed X-ray scan) was more accurate for judging internal carotid artery involvement, and the authors described BRAVO and CT as complementary. Later, a radiosurgery planning study reported that a high-resolution MRI sequence called SPACE (a detailed MRI method for sharper boundaries) produced larger target outlines than standard contrast MRI. In that retrospective planning analysis (modeling work, not patient outcomes), re-planning to match SPACE improved modeled tumor coverage while lowering the estimated dose to the brainstem and cochlea (the hearing organ). This helps explain why your team may order more than one scan or a specific MRI sequence before surgery or radiosurgery, since the tumor target and nearby risk structures can look different depending on the imaging method.

Research covered in: January 2026, July 2026

A new non-surgical option was illustrated in one inoperable case.

In September 2026, one case report described Lu-177 DOTATATE PRRT (a targeted radioactive drug given through the bloodstream) for an inoperable glomus jugulare paraganglioma in a teenager. In that patient, four cycles were followed by stable molecular imaging at 12 months and stable MRI at 15 months. Headaches and double vision improved, while voice symptoms did not change. Because this evidence comes from a single patient and side effects were not reported in the summary, it does not establish typical effectiveness or safety. This case documents that PRRT can be used when surgery is not possible and the tumor shows DOTATATE uptake, with the outcome in this report being stable imaging plus selective symptom changes.

Research covered in: September 2026